nach oben

Erschienen in:

01.08.2005 | Contrast Media

Safety of MR liver specific contrast media

verfasst von: Marie-France Bellin, Judith A. W. Webb, Aart J. Van Der Molen, Henrik S. Thomsen, Sameh K. Morcos, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)

Erschienen in: European Radiology | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Abstract

Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.

Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426–435CrossRef

Bluemke DA, Weber TM, Rubin D et al (2003) Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 228:457–464PubMed

Marti-Bonmati L, Fog AF, Op de Beeck B, Kane P, Fagertun H (2003) Safety and efficacy of mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 13:1685–1692

Ros PR, Freeny PC, Harms SE et al (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488PubMed

Kopp AF, Laniado M, Dammann F et al (1997) MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 204:749–756

Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291

Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688–2698

Bellin MF, Zaim S, Auberton E et al (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193:657–663PubMed

Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ (2001) Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SHU 555 A) J Magn Reson Imaging 14:595–601CrossRef

10.

Reimer P, Balzer T (2003) Ferucarbotran (Resovist), a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276PubMed

11.

Wang YXJ, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331CrossRefPubMed

12.

Stark DD, Weissleder R, Elizondo G et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168:297–301PubMed

13.

Precetti-Morel S, Bellin MF, Ghebontni L et al (1999) Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. Eur Radiol 9:1535–1542CrossRef

14.

Montet X, Lazeyras F, Howarth N et al (2004) Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 29:60–70PubMed

15.

Federle M, Chezmar J, Rubin DL et al (2000) Efficacy and safety of mangafodipir trisodium (MnDPDP) Injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 12:689–701

16.

Elizondo G, Fretz CJ, Stark DD et al (1991) Preclinical evaluation of Mn-DPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73–78

17.

Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quah SC (1991) Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 178:79–82

18.

Thomsen HS, Svendsen O, Klastrup S (2004) Increased manganese concentration in the liver after oral intake. Acad Radiol 11:38–44CrossRefPubMed

19.

Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J (2004) Oral manganese for liver imaging at three different field strengths. Acad Radiol 11:630–636

20.

Gallez B, Bacic G, Swartz HM (1996) Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med 35:14–19

21.

Hustvedt SO, Grant D, Southon TE, Zeck K (1997) Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration. Acta Radiol 38:690–699

22.

Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes HS (1997) MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 38:631–637

23.

Marti-Bonmati L, Torregrosa A, Miguel A, Molla E, Dosda R, Arana E (2001) Safety and efficacy of a bolus administration of mangafodipir trisodium in MR studies (poster). Ninth scientific meeting ISMRM and 14th annual meeting ESMRMB, Glasgow. Proc ISMRM, p 2036

24.

Rummeny E, Ehrenheim C, Gehl HB et al (1991) Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of livers tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 26(Suppl 1):S142–S145; Discussion S150–S155

25.

Aicher KP, Laniado M, Kopp AF, Gronewaller E, Duda SH, Claussen CD (1993) Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging 3:731–737

26.

Wang C, Ahlstrom H, Ekholm S et al (1997) Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicenter study. Acta Radiol 38:643–649PubMed

27.

Blume J, Palmie S, Aue B et al (1994) Pancreatic contrast enhancement with Mn-bis pyridoxal ethylene diamine diacetic acid and the influence of a hormonal stimulation of the pancreas in pigs. Acad Radiol 1:253–260

28.

Mayo-Smith WW, Schima W, Saini S, Slater GJ, McFarland EG (1998) Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium. Am J Roentgenol 170:649–652

29.

Kirchin MA, Pirovano G, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809

30.

Kirchin MA, Pirovano G, Venetianer C, Spinazzi A (2001) Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281–294CrossRefPubMed

31.

Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796CrossRef

32.

Hamm B, Kirchin M, Pirovano G, Spinazzi A (1999) Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr 23(Suppl 1):S53–S60

33.

Caudana R, Morana G, Pirovano GP et al (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)—preliminary results of phase II clinical application. Radiology 199:513–520

34.

Peterstein J, Spinazzi A, Giovagnoni A et al (2000) Evaluation of the efficacy of gadobenate dimeglumine in magnetic resonance imaging of focal liver lesions: a multicenter phase III clinical study. Radiology 215:727–736

35.

Vogl TJ, Stupavsky A, Pegios W et al (1997) Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 205:721–728

36.

Manfredi R, Maresca G, Baron RL et al (1998) Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 8:862–867

37.

Manfredi R, Maresca G, Baron RL et al (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710CrossRefPubMed

38.

Grazioli L, Morana G, Caudana R et al (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathological findings. Invest Radiol 35:25–34

39.

Rosati G, Pirovano G, Spinazzi A (1994) Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 29:S183–S185

40.

Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59–64

41.

Giovagnoni A, Paci E (1996) Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/dimeg). Magn Reson Imaging Clin N Am 4:61–72

42.

Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578CrossRefPubMed

43.

Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7:126–132CrossRefPubMed

44.

Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

45.

Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183PubMed

46.

Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255–262

47.

Huppertz A, Balzer T, Blakeborough A et al for the European EOB Study Group (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275PubMed

48.

Breuer J, Balzer T, Shamsi K, Carter R (2003) Clinical experience from phase II and phase III studies for Gd-EOB-DTPA: a new liver specific MR contrast agent. Eur Radiol 13(Suppl 2):S109

49.

Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ (2002) Gadolinium-ethoxybenzyl–diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680–684CrossRef

Titel: Safety of MR liver specific contrast media
verfasst von: Marie-France Bellin
Judith A. W. Webb
Aart J. Van Der Molen
Henrik S. Thomsen
Sameh K. Morcos
Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
Publikationsdatum: 01.08.2005
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 8/2005
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-004-2612-x

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Safety of MR liver specific contrast media

Abstract

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2005

Aplasia of the N. cochlearis with retrocochlear deafness: the role of thin-slice 3D T2-weighted imaging

CT features of abdominal plasma cell neoplasms

Nutcracker or left renal vein compression phenomenon: multidetector computed tomography findings and clinical significance

Radiological error: analysis, standard setting, targeted instruction and teamworking

CT volumetry of intravertebral cement after kyphoplasty. Comparison of polymethylmethacrylate and calcium phosphate in a 12-month follow-up

3D motion adapted gating (3D MAG): a new navigator technique for accelerated acquisition of free breathing navigator gated 3D coronary MR-angiography

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie